1. Background {#sec0005}
=============

Vitamin C is an essential micronutrient involved in various cellular functions of both the innate and adaptive immune systems. Vitamin C accumulates in phagocytic cells, such as neutrophils, through which it can enhance chemotaxis, phagocytosis, and generation of reactive oxygen species. Vitamin C is also involved with apoptosis and clearance of used neutrophils from sites of infection by macrophages thereby reducing potential tissue damage. Vitamin C also supports differentiation and proliferation of B- and T- cells \[[@bib0005]\].

Vitamin C was proposed as a potential useful agent for coronaviruses in 2003 when the SARS coronavirus was active \[[@bib0010]\] based on available evidence that vitamin C affects severe viral respiratory tract infections. Hemila \[[@bib0010]\], who has continued researching vitamin C for ARI, presented this hypothesis based on the evidence of vitamin C's non-specific effects on severe viral respiratory tract infections. This raises queries regarding vitamin C's potential application in the management of COVID-19.

2. Search strategy {#sec0010}
==================

2.1. Research question {#sec0015}
----------------------

What is the effect of Vitamin C on acute respiratory tract infections in adults when administered at the onset of symptoms?

2.2. Inclusion/exclusion criteria {#sec0020}
---------------------------------

### 2.2.1. Inclusion criteria {#sec0025}

•Systematic review of clinical trials•No age restrictions•Administration at onset of symptoms of acute respiratory tract infection•Oral or intravenous administration of Vitamin C

### 2.2.2. Exclusion criteria {#sec0030}

•Prophylactic administration

2.3. Databases {#sec0035}
--------------

Medline (Ovid), Embase (Ovid), AMED (Ovid), CINAHL (EBSCO)

Search terms (examples)

### 2.3.1. Ovid medline {#sec0040}

(Systematic Review/ or Meta-analysis/ or Systematic Review as Topic/ or Meta-Analysis as Topic/ or Review Literature as Topic/ or (Systematic review or meta analy\$ or metaanaly\$).ti,ab,kw.) not (comment/ or letter/ or editorial/) AND Influenza, Human/ or Influenza A Virus, H1N1 Subtype/ or Influenza A virus/ or Influenza A Virus, H3N2 Subtype/ or Middle East Respiratory Syndrome Coronavirus/ or respiratory tract infections/ or bronchitis/ or common cold/ or exp sinusitis/ or (Influenza or H1N1 or MERS−COV or flu or Bronchit\* or sinusit\* or rhinosinusit\* or rhinit\* or common cold or (respiratory adj2 (infect\* or illness or symptom\* or acute or virus\* or disease))).ti,ab,kw. AND exp Ascorbic Acid/ or (ascorbic acid or Vitamin c).ti,ab,kw ([Table 1](#tbl0005){ref-type="table"} ).Table 1Summary of systematic reviews of vitamin C in the management of acute respiratory infection and disease.Table 1AuthorYearType of ReviewReview durationTypes of Studies includedDatabases UsedIntervention SearchedParticipants included (*condition of interest*)Publication years of including studiesNumber of Studies includedThe number of Types of Studies includedAdministration of Vitamin CTotal number of participants in the Review*Dose*Control or PlaceboN in intervetion and placeboMeasure of OutcomeOutcomeIdentificationMethodsMethods and DoseOutcomesHemila2013Meta-analysisInception to September 2013Intervention studies (randomised/non-randomised; placebo-controlled/non-placebo-controlled)Medline (OVID), Scopus, Cochrane Central Register of Controlled Trialsoral or intravenous vitamin C (ascorbic acid or its salts) as a single or multiple doseschildren and adults of either sex at any age (*common cold-induced asthma*)1980−199032 x randomised-double blind placebo-controlled trial (1 x cross-over) and 1 x self-controlled studyNot specifiedN=791 g/day; 5 g/day; 2 g/single dosePlacebo x 2; no control x 1Vit C (22 + 23 + 9 = 54); placebo (19 + 23 = 42)Frequency of asthma attacks;Incidence of all asthma attacks RR = 0.22; Incidence of severe and moderate asthma attacks RR = 0.11sensitivity to histamine;52 % decrease in proportion of participants sensitive to histamineasthma symptom score;No significant differencePEF;No significant differencePC203.2 fold increaseHemila2004Systematic review1999−2002Intervention studies (placebo-controlled/non-placebo-controlled)Medline, SCISEARCH, EMBASEunrestrictedmilitary personnel; students in crowded lodgings; marathon runners (*respiratory infections)*1942−1996128 x randomised, double-blind, placebo controlled trial; 2x non-placebo-controlled trial; 2 x poorly described methodologyOral; dietary forticationN=13940.05−2 g/day for 7days - 6 monthsPlacebo x 8; Non-placebo x 2; Unclear x 2(vit c = 561; control = 833)Severity of colds1.87 vs 1.97 \[p = .012\]duration of colds (days);No significant differenceIncidence and duration of specific symptoms;Constitutional symptoms: 0.8 v 2.4 days \[p = .045\], 8v21 case \[p = .006\]. Other symptom categories not significanthospital stays (days)10.1 v 16.7 \[p = .012\]hospital admissions18v83 \[p = .09\]Hemila and Chalker2013Systematic review2010−2012Intervention studies (placebo-controlled only)CENTRAL, MEDLINE, Embase, CINAHL, LILACS, Web of ScienceMinimum of 0.2 g/day vitamin CChildren and adults of either gender and any age (*common cold*)1950−200120 (43 additional studies reported prevention rather than treatment outcomes)17 x placebo-controlled trials in community; 3 placebo-controlled laboratory trialsOralN = 32491−8 g/day for 1−4 daysPlaceboVit C = 1968; Control = 1281Duration of coldsNo statistical significanceMean days off work/school (severity)Diff: -0.08 \[p = .048\]Hemila and Louhiala2017Systematic review1950−2011Intervention studies (placebo-controlled/non-placebo-controlled)Cochrane Central Register of Controlled Trials 2011, Medline, EMBASE, Web of ScienceVitamin C only (ascorbic acid or its salts) to one trial group, orally or IV as a single dose (allowed in treatment studies) or multiple doses, with no other nutrient substancesNo age restriction1970−19945 (3 x prophylactic and 2 x treatment trials)2 x \'quasi-placebo control\'; 2 x randomised double-blind placebo-controlled; 1 x no placebo, blinding not described1 x oral dietary fortification; 4 x not specifiedN = 25320.05 to 0.3 g/day for 6 months; 0.2 g/day for up to 4 weeks; 0.3 g/day for unspecified duration; 2 mg per 2000 antibiotic units (0.5--1.6 g/day) or 1 mg per 2000 antibiotic units (0.25 to 0.8 g/day) for unspecified duration2 x no placebo; 1 x low-dose vit. C used as placebo in primary comparison; 2 x placeboVit C = 878; control 1282; placebo 372Community-acquired: Severity of pneumonic episodesReduced severity score (-2.31) at four weeks (p = .053) for patients with higher respiratory scores on admissionCommunity-acquired: Duration of pneumonic episodes−4.0 days in high vitamin C compared with low vitamin C arm (p \< .0001)Community-acquired: Death caused by pneumoniaNo evidence availableHospital-acquired pneumoniaNo evidence availabileRan et al2018Systematic review and meta-analysisInception to March 2018randomised controlled trialsPubMed, Cochrane Library, Elsevier, CNKI, VIP databases, WANFANGvitamin C, added as a regular supplement or administered as needed when cold symptoms developeddefinitive diagnosis of common cold based on laboratory examination, clinical signs, or reported symptoms; no limitation in age, sex, occupation99 x randomised placebo-controlled trialsOraln = 5722 + 1 study n = not reportedfrom 0.67 g per 4 h (4 g over 24 h) to max 10 doses; 1500 mg on day 1 after 500 mg/day; max8 g on day 1all studies used unspecified placeboVit C 2564; control 2076; 1082 unspecified; 1 study not reportedMean duration; nasal congestion or runny nose; sore throat; aching limbs and muscles; mental depression;no statistical significanceFeversignificantly better at reducing fever by about 0.5 days (MD = -0.45, 95 % CI \[-0.78, -0.11\], and P = 0.009)Chest painhigher efficacy in relieving chest pain (MD = -0.40, 95 % CI \[-0.77, -0.03\], and P = 0.03)Chillsbetter at relieving chills by about 8.5 h (MD = -0.36, 95% CI \[-0.65, -0.07\], and P = 0.01)Being confined Indoorsreduced confinement indoors by about 6.5 h (MD = -0.27, 95% CI \[-0.46, -0.08\], and P = 0.004)Zhang and Jativa2018Excluded as participant did not have ARIHeimer2009Excluded as it is a review of reviewsHemila1994Excluded as superceded by Hemila 2013Hemila1999Excluded as supplementation was initiated with healthy subjectsNahas and Balla2011Excluded as the vitamin C part was a review of reviewsRondanelli et al2018Excluded as it is a narrative review

### 2.3.2. CINAHL EBSCO {#sec0045}

PT systematic review OR PT meta-analysis or (MH \"Systematic Review\") OR \"systematic review\" OR (MH \"Cochrane Library\") OR (MH \"Meta Analysis\") OR TX meta analy\* OR TX metaanaly\* OR TX systematic\* review AND (MH \"Influenza+\") OR \"Influenza\" OR (MH \"Influenza A Virus+\") OR (MH \"Influenza, Pandemic (H1N1) 2009\") OR (MH \"Influenza A H5N1\") OR (MH \"Influenzavirus C\") OR (MH \"Influenza B Virus\") OR (MH \"Influenza A Virus, H1N1 Subtype\") OR (MH \"Influenza, Swine\") OR (MH \"Influenza, Human+\") OR (MH \"Influenza, Seasonal\") OR (MH \"Influenza A Virus, H5N1 Subtype\") OR (MH \"Influenza A Virus, H3N2 Subtype\") OR (MH \"Cold+\") OR (MH \"Rhinitis\") OR (MH \"Rhinosinusitis\") OR (MH \"Severe Acute Respiratory Syndrome\") OR (MH \"Sinusitis\") OR (MH \"Bronchitis\") OR (MH \"Bronchitis, Acute\") OR (MH \"Common Cold\") OR (MH \"Respiratory Tract Infections\") OR TX influenza OR TX H5N1 OR TX Common Cold OR TX Rhinitis OR TX Rhinosinusitis OR TX Bronchitis OR TX H3N2 OR (TX Respiratory N2 (infect\* OR illness\* OR symptom OR acute OR virus\* OR disease\*)) AND (MH \"Ascorbic Acid\") OR TX "vitamin c" OR TX "Ascorbid adic"

2.4. Critical appraisal {#sec0050}
-----------------------

The critical appraisal tool used to assess the studies in this rapid review was the BMJ Best practice, appraising systematic reviews (<https://bestpractice.bmj.com/info/toolkit/learn-ebm/appraising-systematic-reviews/>).

3. Rapid review results {#sec0055}
=======================

A search conducted across 4 databases identified 141 review articles. Following the removal of 34 duplicates, 107 review articles were screened by title and abstract for relevance to the study question. Of these, 36 full-text literature reviews were assessed for eligibility against the pre-defined inclusion criteria. A total of 31 articles were removed due to not meeting one or more of the criteria as follows: different patient population (4), study design (14), intervention type (3), not an adult population (3), study setting (1), not written in English (1), indication (2), reviews of reviews (3), the remaining 6 articles were included in this rapid review.

3.1. Critical appraisal {#sec0060}
-----------------------

From the appraisal, three of the five systematic reviews met all the requirements \[[@bib0020],[@bib0025],[@bib0035]\]. One systematic review met the majority of the requirements with the reviewers unable to verify if combined primary studies and combined statistical results were correct \[[@bib0030]\]. The last review was considered to have a lower level of evidence for a systematic review but was still adequate \[[@bib0015]\]. Overall, the level of evidence for the reviews chosen were adequate.

3.2. Summary of findings {#sec0065}
------------------------

All five studies were systematic reviews of randomised controlled trials (RCTs) \[[@bib0005], [@bib0010], [@bib0015], [@bib0020]\]. Two of the studies included a meta-analysis of the included study data \[[@bib0010],[@bib0020]\]. The study population and size, type of respiratory condition, form and dose, and administration route of vitamin C varied across the studies reviewed. The measurement outcomes reviewed by each study varied and were specific to the study focus.

Hemila's 2004 systematic review included eight double-blind randomised-controlled trials, two controlled trials and two studies with poorly defined designs conducted between 1999 and 2002. A total of 1997 participants who were military personal and 587 athletics students in crowded lodgings and marathon runners were allocated to receive vitamin C with doses ranging from 0.05 to 2 g/d for 7 days to 6 months. The severity and duration of respiratory infections were measured in addition to the number of hospital admissions. Overall, positive findings were reported for the severity of respiratory tract infections. The authors suggested the results should be interpreted with caution due to the heterogeneity in study designs including formulation, dose, dietary intake of vitamin C, and the degree of participant's physical exertion \[[@bib0005]\].

Hemilia's 2013 meta-analysis included 3 controlled clinical trials involving 79 (children and adults) evaluating the efficacy of ascorbic acid as single or multiple oral doses for different lengths of time (1 g/d for 14 weeks, 2 g/d one dose at two time points, 5 g/d for 2 weeks) in reducing the incidence and severity of commoncold induced asthma. The primary endpoints across the studies were frequency of asthma attacks, sensitivity to asthma symptoms scores, peak expiratory flow, histamine sensitivity and severity of colds. Significant reductions in the incidence RR = 0.22 (0.06 to 0.81) and severity of asthma attacks RR = 0.22 (0.06 to 0.81) and a 52 % reduction in participants sensitive to histamine sensitivity as measured by PC20 levels \[[@bib0010]\].

Hemila and Chalkers 2013 systematic review included 29 trial comparisons involving a total of 11,306 participants to identify whether vitamin C reduces the incidence, the duration or severity of the common cold. The studies included were from inception to 2013. Collectively the studies involved 10,708 participants from the general community and 598 participants which exercised in extreme conditions. Of the 31 comparisons analysed on people taking vitamin C it was found to reduce the duration of the common cold and the severity of symptoms. No consistent effects were seen on studies evaluating the use of vitamin C during the common cold on duration or severity \[[@bib0015]\].

Hemila and Louhiala \[[@bib0025]\] systematic review included six controlled trials comprising a range of populations (elderly, boarding school male students, burns patients, and military personnel) and varied study designs (non-placebo and placebo-controlled studies). Five studies involved the oral administration or vitamin C (200 mg--3000 mg) in either the prevention (n = 3) or treatment (n = 2) of community -acquired pneumonia and 1 study administered intravenous vitamin C (66 mg/kg/h) during the 24 h after admission to a burns unit to prevent hospital-acquired pneumonia.

The three trials examining continuous oral vitamin intake reported 37 cases of community-acquired pneumonia amongst 2335 people and found that vitamin C reduced the incidence of pneumonia by 80 %. The two treatment trials involving 197 community-acquired pneumonia patients and one prophylactic trial recorded 13 cases of hospital-acquired pneumonia across 37 patients. Rans 2018 meta-analysis including nine RCTs and 3796 participants with a definitive diagnosis of the common cold based on laboratory examination, clinical signs, or reported symptoms from a broad demographic and conducted between 1950 and 2001, evaluating the effectiveness of vitamin C doses ranging from 500 mg to 8 g per day in the treatment of the common cold symptoms. No statistically significant effects were observed for nasal congestion or runny nose, sore throat, aching limbs and muscles or mental depression. Statistically significant improvements were identified for the symptoms of fever (p = 0.009), chest pain (p = 0.03) and chills (0.01) and being confined in doors was reduced by half a day (p = 0.004) \[[@bib0020]\].

4. Clinical significance {#sec0070}
========================

The evidence from this rapid review has identified that oral vitamin C may assist with the symptoms of acute respiratory viral infections (ARI) and common cold-induced asthma but no studies have been identified justifying oral vitamin C for the prevention or treatment of conditions similar to COVID-19. When taken at onset of ARI, oral vitamin C may reduce the duration of AR symptoms including fever, chest pain, chills and bodily aches and pains. It may also reduce the incidence of hospital admission and duration of hospital stays. Evidence related to IV vitamin C from this literature review for COVID-19 or similar conditions is very limited due to the reviews not specifying IV versus oral administration. However, from the studies included in these reviews, further investigation is warranted to examine the effect of IV vitamin C as an adjunct to current medical treatment in acute COVID-19 patients. In addition, oral administration at onset of symptoms to reduce duration and severity of COVID-19 infection also warrants further investigation. Current evidence suggests further studies are needed to better understand the value of both oral and IV vitamin C for ARI, including COVID-19.

Disclaimer {#sec0075}
==========

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice. This is a rapid review of systematic reviews, and it should be noted that the original research papers included in each of the reviews included here, were not individually examined by the authors of this rapid review.

Funding {#sec0080}
=======
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